NCCN Updates Small Cell Lung Cancer Guidelines to Include Lambert-Eaton Myasthenic Syndrome Testing and Treatment
核心洞察
The National Comprehensive Cancer Network (搜索) has updated its small cell lung cancer (搜索) guidelines to include specific recommendations for Lambert-Eaton Myasthenic Syndrome (搜索) (LEMS) diagnosis and treatment.
The guidelines now recommend neurological evaluation with VGCC (搜索) antibody testing and consideration of amifampridine therapy in consultation with neurologists for LEMS management.
LEMS occurs in approximately 3% of small cell lung cancer (搜索) patients, with 90% of cases remaining undiagnosed according to Catalyst Pharmaceuticals data.
The National Comprehensive Cancer Network (搜索) (NCCN) has updated its Clinical Practice Guidelines in Oncology for Small Cell Lung Cancer (搜索) (SCLC) to include critical guidance on Lambert-Eaton Myasthenic Syndrome (搜索) (LEMS), incorporating recommendations for antibody testing and treatment with amifampridine (Firdapse).
The updated guidelines now clearly define LEMS symptoms, notably proximal muscle weakness and autonomic dysfunction. Under the "Signs and Symptoms of Small Cell Lung Cancer (搜索)" section, the guidelines recommend diagnostic evaluation through neurological assessment conducted with consultation of a neurologist, which may include testing for PQ- and N-type voltage-gated calcium channel (VGCC (搜索)) antibodies. In the "Principles of Supportive Care" section, the guidelines advise considering amifampridine therapy with neurology consultation as part of comprehensive care for patients with LEMS.
Clinical Significance of LEMS in SCLC
LEMS is a rare disorder of the neuromuscular junction that can occur as a paraneoplastic syndrome, most often in association with small cell lung cancer (搜索), or as a primary autoimmune condition. The condition is characterized primarily by progressive muscle weakness and arises when antibodies target VGCCs on presynaptic nerve terminals, impairing calcium influx and reducing acetylcholine release.
Approximately half of LEMS cases are tied to an underlying malignancy, with most cases associated with SCLC. Data suggest that LEMS occurs in 3% of patients with SCLC. However, an internal health case database from Catalyst Pharmaceuticals found that 90% of patients with LEMS and SCLC were undiagnosed with the former condition, experiencing disease-related symptoms while undergoing SCLC treatment.
"Early diagnosis of LEMS in SCLC is critical, as it may enable patients to have better outcomes if their LEMS symptoms are effectively treated while fighting SCLC," stated William Andrews, MD, FACP, chief medical officer of Catalyst Pharmaceuticals. "Accurate identification through VGCC (搜索) antibody testing and comprehensive neurological evaluation is essential."
Amifampridine: The Only FDA-Approved LEMS Treatment
Amifampridine, manufactured by Catalyst Pharmaceuticals, is a potassium channel blocker that received FDA approval in 2018 for treating adult and pediatric patients with LEMS. The approval was based on a randomized, double-blind, placebo-controlled phase 3 discontinuation trial (NCT01377922) that included 38 patients with LEMS (median age 54 years; range, 21-88).
After completing an open-label run-in phase, patients were randomized to either continue amifampridine (n = 16) or undergo a 7-day tapering down to placebo (n = 22). The co-primary outcome measures were change from baseline to the end of the discontinuation period in the physician-assessed Quantitative Myasthenia Gravis (QMG) score for muscle weakness and the patient-assessed Subject Global Impression (SGI) score.
During the double-blind period from baseline to day 14, both QMG and SGI scores worsened in both randomized arms; however, there was significantly greater worsening in the placebo arm versus the amifampridine arm for both the QMG (P < .045) and SGI (P = .003) assessments. Amifampridine remains the only FDA-approved therapy specifically for LEMS treatment.
Additional Guideline Updates
The NCCN guidelines included several other notable updates. In pathologic assessment, the guidelines removed the threshold of daily cigarettes (<10 cigarettes/day) and now state that comprehensive molecular profiling can be considered in rare cases for patients with extensive-stage or relapsed SCLC who do not smoke tobacco, lightly smoke, have remote smoking history, or have diagnostic or therapeutic dilemmas.
For imaging, the guidelines now specify that brain MRI is more sensitive than CT for identifying brain metastases and is preferred over CT. In treatment recommendations, carboplatin and etoposide was moved from other recommended regimen to preferred as primary or adjuvant therapy for patients with limited stage disease.
The guidelines also added a note about the significant survival benefit associated with adjuvant durvalumab (Imfinzi) in patients who have not progressed after completion of chemoradiotherapy, though the optimal dose and schedule of radiation therapy in the context of immunotherapy remains undefined.